ntm-1634
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2017 (NCT03046550)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Botulinum neurotoxin type AINHIBITOR
botA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ntm-1634
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03046550 | Phase 1 | Mar 20, 2017 | ICON, National Institute of Allergy and Infectious Diseases (NIAID), Ology Bioservices |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ICON | For profit | 1 | 0 | 1 | 2017 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2017 |
| Ology Bioservices | For profit | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1